Provided by Tiger Trade Technology Pte. Ltd.

3SBIO

15.680
-0.350-2.18%
Volume:13.91M
Turnover:219.00M
Market Cap:39.58B
PE:3.91
High:16.100
Open:15.950
Low:15.600
Close:16.030
52wk High:34.905
52wk Low:14.594
Shares:2.52B
HK Float Shares:2.52B
Volume Ratio:0.68
T/O Rate:0.55%
Dividend:0.26
Dividend Rate:1.68%
EPS(LYR):4.011
ROE:35.88%
ROA:22.68%
PB:1.23
PE(LYR):3.91
PS:1.89

Loading ...

Stock Track | 3SBIO Plummets 7.40% Intraday as Biotech Sector Sees Profit-Taking After ASCO Catalyst Run-Up

Stock Track
·
Jun 02

Movement Alert|3SBio Falls 5.62% in Regular Trading, Biotech Sector Pulls Back After ASCO Catalyst

Market Focus
·
Jun 02

Stock Track | 3SBIO Soars 6.00% at Market Open on Positive ASCO Clinical Data and Pfizer Licensing Deal

Stock Track
·
Jun 01

Movement Alert|3SBio Rises 8% in Regular Trading, ASCO Annual Meeting SSGJ-707 Clinical Data Continues to Drive Momentum

Market Focus
·
Jun 01

Movement Alert|3SBio Rises 5.95% at Open, ASCO Clinical Data for SSGJ-707 Continues to Drive Momentum

Market Focus
·
Jun 01

Stock Track | 3SBio Soars 5.10% Intraday on Positive Clinical Data Presentation at ASCO Annual Meeting

Stock Track
·
May 29

Movement Alert|3SBio Rises 5.1% in Regular Trading, SSGJ-707 Clinical Data Showcased at ASCO Annual Meeting

Market Focus
·
May 29

Stock Track | 3SBIO Plummets 5.09% Intraday on Subsidiary IPO Expiration and Auditor Change

Stock Track
·
May 28

Movement Alert|3SBio Falls 5.25% in Regular Trading, Subsidiary IPO Expiration and Auditor Change Weigh on Sentiment

Market Focus
·
May 28

3SBIO to Appoint KPMG as New Auditor

Stock News
·
May 26

3SBio proposes KPMG as new auditor, replacing EY after 15 years

Reuters
·
May 26

Stock Track | 3SBIO Plummets 5.56% Intraday as Subsidiary Mandi International's IPO Application Expires

Stock Track
·
May 26

Movement Alert|3SBio Falls 5.51% in Regular Trading, Subsidiary Mandi International IPO Application Expires

Market Focus
·
May 26

Zhongtai Securities Maintains "Buy" on 3SBIO, Citing Unlocked Market Value Potential

Deep News
·
May 17

Zhongtai Securities Reiterates "Buy" Rating on 3SBIO (01530), Citing Early-Stage Pipeline with Multiple Potential First-in-Class Candidates for US-China Dual Submissions

Stock News
·
May 15

3SBIO Maintains "Buy" Rating from China Post Securities as Global Value Accelerates Through Multiple Clinical Trials

Stock News
·
May 12

3SBio Adds 34,000 Shares in April After Option Exercises, Keeps Public Float Above 25%

Bulletin Express
·
May 06

Stock Track | 3SBIO Soars 6.03% Intraday as SSS68 Injection Receives IND Approval for Three Indications

Stock Track
·
Apr 30

3SBIO Shares Surge Over 5% as SSS68 Injection Receives IND Approval for Three Indications in China

Stock News
·
Apr 30

三生制药2025年收入近177亿元,核心产品与全球合作驱动业绩大幅增长

Bulletin Express
·
Apr 29